Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...

At first glance, translating clinical outcome assessments (COAs) from their original language (most commonly English) to other languages appears to be no more complicated than other trial planning ...

Axsome Therapeutics has announced that it has successfully completed its late-stage clinical programme evaluating ...

Bristol Myers Squibb (BMS) has shared positive top-line results from two late-stage studies of its oral TYK2 inhibitor ...

Gower is recognised as one of the world’s leading publishers of specialist business and management books and resources. Our publishing programme covers many of the main business processes and ...

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us a unique perspective in healthcare marketing. We’re ideally ...

Events 4 Healthcare specialise in delivering bespoke events for the Healthcare and Pharmaceutical industry. We conceive and deliver Joint Working projects and produce medical education programmes, ...

CHCR is a research centre offering healthcare communication consultancy, professional development and training including the first UK Postgraduate Certificate in Health Communications.

Our broad arsenal of services and solutions now spans the entire value chain. By expanding the methodologies of MarketRx, a highly respected firm acquired in 2007, our offerings now include: ...

Malana research consult international (MARECI) is an independent full-service market and social Research agency, operating across East African Sub- Region with head office in Kampala, Uganda. Malana ...

Windrose Consulting Group Founded in 2015, Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize the commercial value of their ...

The Clinical Trial Company (TCTC) targets medium size clinical trials and novel products which lack a classical road map to the market. Large CROs prioritise studies from the big pharma companies, for ...